We hope that our present data may inspire further preclinical and clinical work, including assessment of in vivo feasibility, and search for predictive biomarkers, to identify AML patients who might most benefit from possible therapeutic targeting of eIF4A3 in the future. This evidence concerns the gene EIF4A3 and acute myeloid leukemia.